CVS eye drops class action claims product falsely advertised as safe, effective

CVS eye drops class action lawsuit overview:

• Who: Plaintiff Georgiann Jordan filed a class action lawsuit against CVS Pharmacy Inc.
• Why: CVS eye drops are allegedly not “safe and effective” as advertised because they contain a potentially harmful preservative.
• Where: The CVS class action lawsuit was filed in New York federal court.

How to find help: Consumers who suffered from a bacterial infection, vision loss, other injury or death after using EzriCare eye drops, Delsam Eye Drops or Delsam eye ointment could join a lawsuit investigation.

CVS Pharmacy Inc. falsely advertises its homeopathic pink eye drops product as safe and effective even though it is allegedly not capable of delivering the promised results, according to a class action lawsuit filed Sept. 17 in New York federal court.

Plaintiff Georgiann Jordan says she purchased the drops because she believed the claims on the front label indicating the product “Relieves: Redness, Burning, Watery discharge, Gritty sensation.”

Based on the label’s representations, Jordan says she believed that the product would do what it claimed. She also says that she expected the CVS eye drops to be safe and effective because she trusts the CVS Health brand to be a respected and credible store.

Had she known that the CVS eye drops contained a potentially harmful preservative, Jordan would not have paid as much for them or would not have purchased them at all, the CVS class action lawsuit alleges.

CVS eye drops contain potentially harmful silver sulfate preservative, plaintiff says

The CVS class action lawsuit notes that products designed to be administered directly into the eyes pose a greater risk of harm because eye drops bypass some of the body’s natural defenses.

The U.S. Food and Drug Administration has also expressed “significant concerns regarding [the] safety” of the use of silver sulfate, a preservative that may cause irreversible bluish-gray discoloration of the skin and eyes when used over a long period of time.

The FDA reportedly declared the drops violated a regulation stating that ophthalmic preservatives should be “suitable and harmless” due to the addition of silver sulfate as a preservative.

Jordan filed the class action lawsuit on behalf of herself and a proposed class of other New Yorkers who purchased the allegedly falsely advertised product in the state.

CVS recently reached a nearly $4 million class action settlement over claims it falsely advertised lidocaine products as “maximum strength.” If you purchased certain CVS lidocaine products, you have until Nov. 20, 2023, to file a claim for a potential cash payment.

What do you think about the claims that CVS eye drops contain a potentially dangerous preservative? Join the discussion in the comments.

Jordan is represented by Spencer Sheehan of Sheehan & Associates PC.

The CVS eye drops class action lawsuit is Georgiann Jordan v. CVS Pharmacy Inc., Case No. 1:23-cv-00979, in the U.S. District Court for the Western District of New York, Buffalo Division.

Read About More Class Action Lawsuits & Class Action Settlements:

• Albertsons class action alleges company falsely advertises lidocaine patch benefits
• Culturelle class action alleges company falsely advertises Ultimate Balance for Antibiotics products
• Walgreens agrees to $44M settlement over allegedly defective Theranos blood tests
• Philips CPAP class action alleges company knew of foam degradation issues in 2015